{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:50:53Z","timestamp":1793040653171,"version":"4.5.0"},"reference-count":145,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006181","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado da Bahia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Tuberculosis (TB) is a lethal disease and remains one of the top ten causes of mortality by an infectious disease worldwide. It can also result in significant morbidity related to persistent inflammation and tissue damage. Pulmonary TB treatment depends on the prolonged use of multiple drugs ranging from 6 months for drug-susceptible TB to 6\u201320 months in cases of multi-drug resistant disease, with limited patient tolerance resulting from side effects. Treatment success rates remain low and thus represent a barrier to TB control. Adjunct host-directed therapy (HDT) is an emerging strategy in TB treatment that aims to target the host immune response to\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    in addition to antimycobacterial drugs. Combined multi-drug treatment with HDT could potentially result in more effective therapies by shortening treatment duration, improving cure success rates and reducing residual tissue damage. This review explores the rationale and challenges to the development and implementation of HDTs through a succinct report of the medications that have completed or are currently being evaluated in ongoing clinical trials.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2022.970408","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T02:16:19Z","timestamp":1663899379000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs"],"prefix":"10.3389","volume":"9","author":[{"given":"Juan M.","family":"Cubillos-Angulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bet\u00e2nia M. F.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda B.","family":"Arriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Barreto-Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Ara\u00fajo-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina D.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caian L.","family":"Vinhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klauss","family":"Villalva-Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o P.","family":"Miguez-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo P.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno B.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"B1","year":"2021","journal-title":"Global Tuberculosis Report 2021."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0264-2021","article-title":"COVID-19 and tuberculosis: the double whammy of respiratory pathogens.","volume":"31","author":"Shariq","year":"2022","journal-title":"Eur Respir Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1590\/s0102-311x1999000300003","article-title":"Tuberculosis in the twentieth century: time-series mortality in Sao Paulo, Brazil, 1900-97.","volume":"15","author":"Antunes","year":"1999","journal-title":"Cad Saude Publica."},{"key":"B4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/003335491012500307","article-title":"Trends in tuberculosis mortality in the United States, 1990-2006: a population-based case-control study.","volume":"125","author":"Jung","year":"2010","journal-title":"Public Health Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1164\/rccm.200402-140OE","article-title":"A century of tuberculosis.","volume":"169","author":"Murray","year":"2004","journal-title":"Am J Respir Crit Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1001\/archinte.167.22.2443","article-title":"Trends in tuberculosis\/human immunodeficiency virus comorbidity, United States, 1993-2004.","volume":"167","author":"Albalak","year":"2007","journal-title":"Arch Intern Med."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-6399-8","article-title":"Challenges and opportunities for eliminating tuberculosis \u2013 leveraging political momentum of the UN high-level meeting on tuberculosis.","volume":"19","author":"Sakamoto","year":"2019","journal-title":"BMC Public Health."},{"key":"B8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.rppnen.2017.10.009","article-title":"New drugs and perspectives for new anti-tuberculosis regimens.","volume":"24","author":"Tiberi","year":"2018","journal-title":"Pulmonology."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2022.021","article-title":"The dark side of the COVID-19 treatments on Mycobacterium tuberculosis infection.","volume":"14","author":"De Maio","year":"2022","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1128\/AAC.00749-08","article-title":"New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.","volume":"53","author":"van den Boogaard","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/joim.12256","article-title":"Inflammation and tuberculosis: host-directed therapies.","volume":"277","author":"Zumla","year":"2015","journal-title":"J Intern Med."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01790","article-title":"Host-directed therapy in tuberculosis: targeting host metabolism.","volume":"11","author":"Kim","year":"2020","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9010021","article-title":"Host-directed therapy as a novel treatment strategy to overcome tuberculosis: targeting immune modulation.","volume":"9","author":"Ahmed","year":"2020","journal-title":"Antibiotics (Basel)."},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections.","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"B15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri3813","article-title":"Advancing host-directed therapy for tuberculosis.","volume":"15","author":"Wallis","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis.","volume":"2","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5114\/ceji.2020.94711","article-title":"Understanding the early host immune response against Mycobacterium tuberculosis.","volume":"45","author":"Jee","year":"2020","journal-title":"Cent Eur J Immunol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00350","article-title":"Immune response to Mycobacterium tuberculosis: a narrative review.","volume":"7","author":"de Martino","year":"2019","journal-title":"Front Pediatr."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01553","article-title":"Host-pathogen interaction as a novel target for host-directed therapies in tuberculosis.","volume":"11","author":"Abreu","year":"2020","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/path.5407","article-title":"Effects of host-directed therapies on the pathology of tuberculosis.","volume":"250","author":"Tsenova","year":"2020","journal-title":"J Pathol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/139127","article-title":"The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?","volume":"2012","author":"Silva Miranda","year":"2012","journal-title":"Clin Dev Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imr.12951","article-title":"Host-directed therapy to combat mycobacterial infections.","volume":"301","author":"Kilinc","year":"2021","journal-title":"Immunol Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/onc.2016.182","article-title":"VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.","volume":"36","author":"Rohrig","year":"2017","journal-title":"Oncogene."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01755","article-title":"Strategies to improve vaccine efficacy against tuberculosis by targeting innate immunity.","volume":"8","author":"Schaible","year":"2017","journal-title":"Front Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.cytogfr.2010.10.004","article-title":"IL-17 and Th17 cells in tuberculosis.","volume":"21","author":"Torrado","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00171","article-title":"Host-directed therapeutic strategies for tuberculosis.","volume":"4","author":"Kolloli","year":"2017","journal-title":"Front Med (Lausanne)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","article-title":"Therapeutic host-directed strategies to improve outcome in tuberculosis.","volume":"13","author":"Young","year":"2020","journal-title":"Mucosal Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1039\/C7MD00528H","article-title":"Narrow-spectrum antibacterial agents.","volume":"9","author":"Melander","year":"2018","journal-title":"Medchemcomm."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.613149","article-title":"One size fits all? Not in in vivo modeling of tuberculosis chemotherapeutics.","volume":"11","author":"Yang","year":"2021","journal-title":"Front Cell Infect Microbiol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105323","article-title":"In vitro and in vivo studies for assessing the immune response and protection-inducing ability conferred by Fasciola hepatica-derived synthetic peptides containing B- and T-cell epitopes.","volume":"9","author":"Rojas-Caraballo","year":"2014","journal-title":"PLoS One."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-56905-1","author":"Karakousis","year":"2021","journal-title":"Advances in Host-Directed Therapies Against Tuberculosis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000457640","article-title":"Malnutrition and drugs: clinical implications.","volume":"15","author":"Mehta","year":"1990","journal-title":"Dev Pharmacol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/infdis\/jiy712","article-title":"Remembering the host in tuberculosis drug development.","volume":"219","author":"Frank","year":"2019","journal-title":"J Infect Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"39","author":"Coussens","year":"2013","journal-title":"Science."},{"key":"B36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/2049936114528173","article-title":"Extrapulmonary tuberculosis: are statistical reports accurate?","volume":"2","author":"Kulchavenya","year":"2014","journal-title":"Ther Adv Infect Dis."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4312-9","article-title":"Treatment outcomes and risk factors of extra-pulmonary tuberculosis in patients with co-morbidities.","volume":"19","author":"Khan","year":"2019","journal-title":"BMC Infect Dis."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25392","article-title":"Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low- and middle-income countries: a multicohort study.","volume":"22","author":"Zurcher","year":"2019","journal-title":"J Int AIDS Soc."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-020-00227-1","article-title":"Treatment outcomes of extrapulmonary tuberculosis in Bahawalpur, Pakistan; a record review.","volume":"13","author":"Atif","year":"2020","journal-title":"J Pharm Policy Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature13489","article-title":"Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk.","volume":"511","author":"Mayer-Barber","year":"2014","journal-title":"Nature."},{"key":"B41","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000490478","article-title":"Host directed therapies for tuberculosis: futures strategies for an ancient disease.","volume":"63","author":"Palucci","year":"2018","journal-title":"Chemotherapy."},{"key":"B42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.","volume":"23","author":"Schror","year":"1997","journal-title":"Semin Thromb Hemost."},{"key":"B43","first-page":"252","article-title":"An overview of the physiology and pharmacology of aspirin and nonsteroidal anti-inflammatory drugs.","volume":"28","author":"Koester","year":"1993","journal-title":"J Athl Train."},{"key":"B44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","article-title":"Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention.","volume":"36","author":"Ornelas","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tube.2013.09.004","article-title":"Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis.","volume":"94","author":"Marzo","year":"2014","journal-title":"Tuberculosis (Edinb)."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070923","article-title":"Use of antiplatelet agents and survival of tuberculosis patients: a population-based cohort study.","volume":"8","author":"Lee","year":"2019","journal-title":"J Clin Med."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00798","article-title":"A beneficial effect of low-dose aspirin in a murine model of active tuberculosis.","volume":"9","author":"Kroesen","year":"2018","journal-title":"Front Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jac\/dkl486","article-title":"Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.","volume":"59","author":"Byrne","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/01.inf.0000261126.60283.cf","article-title":"Coagulant and fibrinolytic status in tuberculous meningitis.","volume":"26","author":"Schoeman","year":"2007","journal-title":"Pediatr Infect Dis J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1164\/rccm.201710-2102OC","article-title":"Platelets regulate pulmonary inflammation and tissue destruction in tuberculosis.","volume":"198","author":"Fox","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.33478","article-title":"A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults.","volume":"7","author":"Mai","year":"2018","journal-title":"Elife."},{"key":"B52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2010.03.025","article-title":"Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial.","volume":"293","author":"Misra","year":"2010","journal-title":"J Neurol Sci."},{"key":"B53","year":"2021","journal-title":"Phase 2b Randomized Double-blind, Placebo-controlled Trial to Estimate the Potential Efficacy and Safety of Two Repurposed Drugs, Acetylsalicylic Acid and Ibuprofen, for Use as Adjunct Therapy Added to, and Compared With, the Standard WHO-recommended TB Regimen (SMA-TB). [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B54","year":"2021","journal-title":"A Prospective Randomized Controlled Trial of Adjunctive N-acetylcysteine (NAC) in Adult Patients With Pulmonary Tuberculosis: A Sub-study of TB Sequel. [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B55","year":"2019","journal-title":"An Open Label Randomized Phase 2 Clinical Trial to Assess Safety and Tolerability of RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV\/Aids and Pulmonary Tuberculosis. [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.12.04015","article-title":"Effects of Vitamin D supplementation on resolution of fever and cough in children with pulmonary tuberculosis: A randomized double-blind controlled trial in Indonesia.","volume":"12","author":"Tamara","year":"2022","journal-title":"J Glob Health."},{"key":"B57","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5588\/ijtld.13.0460","article-title":"Change in serum CXCL10 levels during anti-tuberculosis treatment depends on vitamin D status [Short communication].","volume":"18","author":"Hasan","year":"2014","journal-title":"Int J Tuberc Lung Dis."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070032","article-title":"L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial.","volume":"8","author":"Ralph","year":"2013","journal-title":"PLoS One."},{"key":"B59","author":"Shafique","year":"2014","journal-title":"Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial. [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B60","author":"Rojas","year":"2015","journal-title":"Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases. [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B61","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S1473-3099(15)70053-8","article-title":"Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial.","volume":"15","author":"Daley","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3203-9","article-title":"Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D3 as host directed therapy.","volume":"18","author":"Rekha","year":"2018","journal-title":"BMC Infect Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/joim.12767","article-title":"Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia.","volume":"284","author":"Bekele","year":"2018","journal-title":"J Intern Med."},{"key":"B64","year":"2011","journal-title":"Role of Oral Vitamin D as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters. (Double-blind, Randomized, Placebo-Controlled, Clinical Trial). [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B65","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.","volume":"9","author":"Wallis","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B66","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1079\/BJN20051684","article-title":"The effect of multi-vitamin\/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two-by-two factorial trial in Mwanza.","volume":"95","author":"Range","year":"2006","journal-title":"Tanzania. Br J Nutr."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta23020","article-title":"Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis","volume":"23","author":"Martineau","year":"2019","journal-title":"Health Technol Assess."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141895","article-title":"Doxycycline host-directed therapy in human pulmonary tuberculosis.","volume":"131","author":"Miow","year":"2021","journal-title":"J Clin Invest."},{"key":"B69","first-page":"854","article-title":"Micronutrient supplements and mortality of HIV-infected adults with pulmonary TB: a controlled clinical trial.","volume":"11","author":"Semba","year":"2007","journal-title":"Int J Tuberc Lung Dis."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3945\/ajcn.113.082255","article-title":"Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: a randomized controlled trial.","volume":"100","author":"Lodha","year":"2014","journal-title":"Am J Clin Nutr."},{"key":"B71","author":"Thienemann","year":"2020","journal-title":"Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion in HIV-infected and HIV-uninfected Adults Measured by FDG-PET\/CT. [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B72","author":"Olufemi","year":"2021","journal-title":"Repurposing a Lipid Lowering Drug to Treat Tuberculosis: Effectiveness of Statins as Adjuvant to Treatment of Pulmonary Tuberculosis in Nigeria. [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B73","year":"2020","journal-title":"Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct. [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B74","author":"Phuphuakrat","year":"2022","journal-title":"Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis: A Randomized Controlled Trial. [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B75","author":"MD","year":"2022","journal-title":"A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV. [Clinical trial registration]. Clinicaltrials.Gov."},{"key":"B76","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/infdis\/jit153","article-title":"Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment.","volume":"208","author":"Ivanyi","year":"2013","journal-title":"J Infect Dis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/infdis\/jit152","article-title":"Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.","volume":"208","author":"Vilaplana","year":"2013","journal-title":"J Infect Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/infdis\/jit476","article-title":"Low-dose aspirin and ibuprofen\u2019s sterilizing effects on Mycobacterium tuberculosis suggest safe new adjuvant therapies for tuberculosis.","volume":"208","author":"Eisen","year":"2013","journal-title":"J Infect Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1753465812437563","article-title":"N-acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.","volume":"6","author":"Sadowska","year":"2012","journal-title":"Ther Adv Respir Dis."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.602589","article-title":"Adjunct N-acetylcysteine treatment in hospitalized patients with HIV-associated tuberculosis dampens the oxidative stress in peripheral blood: results from the RIPENACTB study trial.","volume":"11","author":"Safe","year":"2020","journal-title":"Front Immunol."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5907839","article-title":"N-acetyl cysteine as an adjunct in the treatment of tuberculosis.","volume":"2020","author":"Ejigu","year":"2020","journal-title":"Tuberc Res Treat."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-016-0872-7","article-title":"N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions.","volume":"16","author":"Amaral","year":"2016","journal-title":"BMC Microbiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/2229-3485.210450","article-title":"N-acetylcysteine as an add-on to directly observed therapy short-I therapy in fresh pulmonary tuberculosis patients: a randomized, placebo-controlled, double-blinded study.","volume":"8","author":"Mahakalkar","year":"2017","journal-title":"Perspect Clin Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1097\/MEG.0b013e32833aa11b","article-title":"Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.","volume":"22","author":"Baniasadi","year":"2010","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"8251","DOI":"10.3390\/nu7105392","article-title":"Mechanisms underlying the regulation of innate and adaptive immunity by vitamin D.","volume":"7","author":"Wei","year":"2015","journal-title":"Nutrients."},{"key":"B86","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1139\/cjpp-2014-0386","article-title":"Vitamin D: immuno-modulation and tuberculosis treatment.","volume":"93","author":"Selvaraj","year":"2015","journal-title":"Can J Physiol Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000486536","article-title":"Vitamin D: classic and novel actions.","volume":"72","author":"Gil","year":"2018","journal-title":"Ann Nutr Metab."},{"key":"B88","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.4049\/jimmunol.0803736","article-title":"Vitamin D-directed rheostatic regulation of monocyte antibacterial responses.","volume":"182","author":"Adams","year":"2009","journal-title":"J Immunol."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/nu12072097","article-title":"Immunologic effects of vitamin D on human health and disease.","volume":"9","author":"Charoenngam","year":"2020","journal-title":"Nutrients."},{"key":"B90","first-page":"325","article-title":"Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection.","volume":"11","author":"Wu","year":"2011","journal-title":"Discov Med."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-017-0195-7","article-title":"Vitamin D deficiency among newly diagnosed tuberculosis patients and their household contacts: a comparative cross-sectional study.","volume":"75","author":"Workineh","year":"2017","journal-title":"Arch Public Health."},{"key":"B92","first-page":"3","article-title":"The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion.","volume":"38","author":"Nursyam","year":"2006","journal-title":"Acta Med Indones."},{"key":"B93","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1039\/c9fo02751c","article-title":"Adjunctive vitamin A and D during pulmonary tuberculosis treatment: a randomized controlled trial with a 2 x 2 factorial design.","volume":"11","author":"Wang","year":"2020","journal-title":"Food Funct."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138340","article-title":"Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial.","volume":"10","author":"Mily","year":"2015","journal-title":"PLoS One."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3945\/ajcn.115.113886","article-title":"High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial.","volume":"102","author":"Tukvadze","year":"2015","journal-title":"Am J Clin Nutr."},{"key":"B96","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1164\/rccm.201705-0936OC","article-title":"High-dose vitamin D3 during tuberculosis treatment in Mongolia. A randomized controlled trial.","volume":"196","author":"Ganmaa","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/joim.12767","article-title":"Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia.","volume":"284","author":"Bekele","year":"2018","journal-title":"J Intern Med."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006086.pub4","article-title":"Nutritional supplements for people being treated for active tuberculosis.","volume":"2016","author":"Grobler","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B99","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/rr33","article-title":"Matrix metalloproteinases in lung biology.","volume":"2","author":"Parks","year":"2001","journal-title":"Respir Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nri1418","article-title":"Matrix metalloproteinases as modulators of inflammation and innate immunity.","volume":"4","author":"Parks","year":"2004","journal-title":"Nat Rev Immunol."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061350","article-title":"Matrix metalloproteinases in pulmonary and central nervous system tuberculosis-a review.","volume":"20","author":"Rohlwink","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12649","article-title":"Matrix metalloproteinases: expression, regulation and role in the immunopathology of tuberculosis.","volume":"52","author":"Sabir","year":"2019","journal-title":"Cell Prolif."},{"key":"B103","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/path.4432","article-title":"Mycobacterium tuberculosis dysregulates MMP\/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation.","volume":"235","author":"Kubler","year":"2015","journal-title":"J Pathol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1164\/rccm.201311-2106PP","article-title":"Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.","volume":"190","author":"Ong","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1172\/JCI57423","article-title":"MMPs in tuberculosis: granuloma creators and tissue destroyers.","volume":"121","author":"Salgame","year":"2011","journal-title":"J Clin Invest."},{"key":"B106","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0022-510X(99)00303-2","article-title":"Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis.","volume":"173","author":"Matsuura","year":"2000","journal-title":"J Neurol Sci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.4049\/jimmunol.166.6.4223","article-title":"Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo.","volume":"166","author":"Price","year":"2001","journal-title":"J Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jns.2004.02.008","article-title":"Persistent increase of matrix metalloproteinases in cerebrospinal fluid of tuberculous meningitis.","volume":"220","author":"Lee","year":"2004","journal-title":"J Neurol Sci."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141895","article-title":"Doxycycline host-directed therapy in human pulmonary tuberculosis.","volume":"131","author":"Miow","year":"2021","journal-title":"J Clin Invest."},{"key":"B110","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1164\/rccm.201110-1769OC","article-title":"Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.","volume":"185","author":"Walker","year":"2012","journal-title":"Am J Respir Crit Care Med."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061333","article-title":"Induced sputum MMP-1, \u20133 & \u20138 concentrations during treatment of tuberculosis.","volume":"8","author":"Ugarte-Gil","year":"2013","journal-title":"PLoS One."},{"key":"B112","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1183\/09031936.00113713","article-title":"Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis.","volume":"43","author":"Alsaad","year":"2014","journal-title":"Eur Respir J."},{"key":"B113","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1080\/10408398.2016.1160362","article-title":"The vicious cycle of vitamin a deficiency: a review.","volume":"57","author":"Wiseman","year":"2017","journal-title":"Crit Rev Food Sci Nutr."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2019.102268","article-title":"Effectiveness of micronutrients supplement in patients with active tuberculosis on treatment: systematic review\/meta-analysis.","volume":"48","author":"Cabrera Andrade","year":"2020","journal-title":"Complement Ther Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/ajcn\/75.4.720","article-title":"A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status.","volume":"75","author":"Karyadi","year":"2002","journal-title":"Am J Clin Nutr."},{"key":"B116","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1079\/bjn20051684","article-title":"The effect of multi-vitamin\/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two-by-two factorial trial in Mwanza, Tanzania.","volume":"95","author":"Range","year":"2006","journal-title":"Br J Nutr."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3945\/ajcn.113.082255","article-title":"Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: a randomized controlled trial.","volume":"100","author":"Lodha","year":"2014","journal-title":"Am J Clin Nutr."},{"key":"B118","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1128\/JB.00488-09","article-title":"Mycobacterium tuberculosis is able to accumulate and utilize cholesterol.","volume":"191","author":"Brzostek","year":"2009","journal-title":"J Bacteriol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/jac\/dku166","article-title":"Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.","volume":"69","author":"Skerry","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7404","article-title":"Anti-tuberculous effects of statin therapy: a review of literature.","volume":"12","author":"Tahir","year":"2020","journal-title":"Cureus."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00910","article-title":"Mycobacterium tuberculosis infection-driven foamy macrophages and their implications in tuberculosis control as targets for host-directed therapy.","volume":"11","author":"Shim","year":"2020","journal-title":"Front Immunol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jit550","article-title":"Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.","volume":"209","author":"Parihar","year":"2014","journal-title":"J Infect Dis."},{"key":"B123","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1073\/pnas.0711159105","article-title":"Mycobacterial persistence requires the utilization of host cholesterol.","volume":"105","author":"Pandey","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02097","article-title":"Simvastatin enhances the immune response against Mycobacterium tuberculosis.","volume":"10","author":"Guerra-De-Blas","year":"2019","journal-title":"Front Microbiol."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014145","article-title":"Statins inhibit angiotensin II\/Smad pathway and related vascular fibrosis, by a TGF-beta-independent process.","volume":"5","author":"Rodrigues Diez","year":"2010","journal-title":"PLoS One."},{"key":"B126","first-page":"355","article-title":"Rosuvastatin inhibits TGF-beta1 expression and alleviates myocardial fibrosis in diabetic rats.","volume":"68","author":"Ma","year":"2013","journal-title":"Pharmazie."},{"key":"B127","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1128\/AAC.01826-13","article-title":"Statins increase rifampin mycobactericidal effect.","volume":"58","author":"Lobato","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/jac\/dkw014","article-title":"Statin adjunctive therapy shortens the duration of TB treatment in mice.","volume":"71","author":"Dutta","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"B129","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.chest.2017.04.170","article-title":"Statin use is associated with a lower risk of TB.","volume":"152","author":"Su","year":"2017","journal-title":"Chest."},{"key":"B130","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/thoraxjnl-2015-207052","article-title":"Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort.","volume":"71","author":"Lai","year":"2016","journal-title":"Thorax."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00597","article-title":"Population-based case-control study assessing the association between statins use and pulmonary tuberculosis in Taiwan.","volume":"8","author":"Liao","year":"2017","journal-title":"Front Pharmacol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"11369","DOI":"10.3390\/ijms160511369","article-title":"Statin, calcium channel blocker and beta blocker therapy may decrease the incidence of tuberculosis infection in elderly Taiwanese patients with type 2 diabetes.","volume":"16","author":"Lee","year":"2015","journal-title":"Int J Mol Sci."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7110381","article-title":"Statin for tuberculosis and pneumonia in patients with asthma(-)chronic pulmonary disease overlap syndrome: a time-dependent population-based cohort study.","volume":"7","author":"Yeh","year":"2018","journal-title":"J Clin Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/bcp.14142","article-title":"Opposite effects of statins on the risk of tuberculosis and herpes zoster in patients with diabetes: a population-based cohort study.","volume":"86","author":"Pan","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00121","article-title":"Statin use may be associated with reduced active tuberculosis infection: a meta-analysis of observational studies.","volume":"7","author":"Li","year":"2020","journal-title":"Front Med (Lausanne)."},{"key":"B136","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2337\/cd15-0045","article-title":"Metformin use in practice: compliance with guidelines for patients with diabetes and preserved renal function.","volume":"35","author":"Salber","year":"2017","journal-title":"Clin Diabetes."},{"key":"B137","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.tube.2016.09.008","article-title":"Metformin: candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients.","author":"Restrepo","year":"2016","journal-title":"Tuberculosis (Edinb)."},{"key":"B138","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/978-3-642-17214-4_13","article-title":"AMP-activated protein kinase and metabolic control.","volume":"203","author":"Viollet","year":"2011","journal-title":"Handb Exp Pharmacol."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009885","article-title":"Metformin as adjunct antituberculosis therapy.","volume":"6","author":"Singhal","year":"2014","journal-title":"Sci Transl Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e00652","DOI":"10.1128\/AAC.00652-17","article-title":"Metformin adjunctive therapy does not improve the sterilizing activity of the first-line antitubercular regimen in mice.","volume":"61","author":"Dutta","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B141","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1016\/j.celrep.2019.11.034","article-title":"Compromised metabolic reprogramming is an early indicator of CD8(+) T cell dysfunction during chronic Mycobacterium tuberculosis infection.","volume":"29","author":"Russell","year":"2019","journal-title":"Cell Rep."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19095-z","article-title":"Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits.","volume":"11","author":"Bohme","year":"2020","journal-title":"Nat Commun."},{"key":"B143","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3904\/kjim.2017.249","article-title":"The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus.","volume":"33","author":"Lee","year":"2018","journal-title":"Korean J Intern Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/cid\/cix819","article-title":"Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment.","volume":"66","author":"Degner","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10096-018-3242-6","article-title":"Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up.","volume":"37","author":"Ma","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.970408\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T02:16:37Z","timestamp":1663899397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.970408\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":145,"alternative-id":["10.3389\/fmed.2022.970408"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.970408","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"article-number":"970408"}}